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CASE REPORT
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Abstract
Cancer patients are at a higher risk of complications such as venous thromboembolism (VTE). This risk increases in
patients who receive chemotherapy. Despite the increased risk, common locations for VTE are similar to those in patients without cancer. Chemotherapy-port-related thrombosis represents a rare complication due to the location and
frequent use of access (with Heparin ﬂushes) as part of the standard care. Attention should be made to this rare
complication, which may progress to superior vena cava (SVC) syndrome. SVC syndrome typically presents in females
around the age of 57 years old. Management of this syndrome can be difﬁcult and generally requires the initiation of
systemic anticoagulation therapy. Here, we present a rare case of a 45-year-old female who presented to the Emergency
Department with right arm swelling, found to be secondary to her chemo port thrombosis, causing SVC syndrome.
Keywords: SVC syndrome, Breast cancer, Port thrombosis

1. Introduction

S

VC syndrome has been found to be a complication associated with cancer patients, with a
further increase in the development of this syndrome if patients receive chemotherapy through
indwelling catheters. Patients with SVC syndrome
can present acutely due to the rapid rate of clot
development without the body's ability to adjust and
develop collateral circulation. Treatment consists of
treating the underlying cause, such as removal,
replacement, or thrombolysis of the catheter itself,
followed by the use of anti-coagulation. Here, we
discuss a case of a chemo port associated with SVC
syndrome in a 45-year-old female with inﬂammatory breast cancer, who ultimately required urgent
removal of her central venous catheter and initiation
of systemic anticoagulation therapy.

2. Case report
A 45-year-old Hispanic female with a past medical
of inﬂammatory breast cancer of the left breast

status post adjuvant chemotherapy followed by a
modiﬁed radical mastectomy, presented to the
Emergency Department (ED) with a chief complaint
of neck swelling for 5 days with associated facial
swelling, RUE swelling, and pain with cervical
rotation. At the time of presentation, the patient
complained of an intermittent headache over her
frontal and occipital area rated 8/10 in severity with
associated blurry vision for one day. She denied
shortness of breath, chest pain, nausea, vomiting, or
abdominal pain.
In terms of the patient's past oncologic history,
she was diagnosed with biopsy positive ductal
adenocarcinoma that was ER/PR negative with
HER2 IHC þ3 positive with Ki 67 < 10%. The patient completed 6 cycles of Taxotere, Carboplatin,
Herceptin, and Perjeta (TCHP) chemotherapy
4 months prior to the current presentation with the
use of a chemotherapy port, which she tolerated
well. Following neoadjuvant chemotherapy, the
patient underwent left radical mastectomy
2 months prior to the current admission and after
surgery, she had cancer staging of ypTis (DCIS) N0
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(iþ) Mx. In the interim, the patient was compliant
with receiving port ﬂushes with heparin every
6 weeks. The patient was initiated on maintenance
therapy of Herceptin and Perjeta the day prior to
admission through the peripheral line due to her
swelling. She did not receive treatment with
Tamoxifen. The patient denied tobacco or illicit
drug use, and her family history was negative for
malignancy or deep vein thrombosis.
Physical exam was signiﬁcant for facial and neck
swelling. Laboratory studies were signiﬁcant for
normocytic anemia with a hemoglobin of 8.7 g/dL
(reference range 12.0e16.0), and a hematocrit level
of 28.9% (reference range 36.0e46.0) with a mean
corpuscular volume of 83.3 fL (reference range
80e100). Prothrombin time was 12.9 s (reference
range 12.2e14.9), PTT was 27.5 s (reference range
21.3e35.1), and INR was 1.0 (reference range 1.1).
Chest XR was notable for new minimal blunting of
bilateral costophrenic angles posteriorly, most
indicative of trace pleural effusions. Venous ultrasound of the right upper extremity was notable for
focal occlusion of the dome of the right internal jugular vein proximally by deep vein thrombosis with
occlusion of the right chemotherapy port, and with
focal thrombus in the distal basilic vein. The patient
was admitted for further management of the focal
occlusion of her right internal jugular vein.
A CT angiogram of the neck and chest was signiﬁcant for an occlusive thrombosis in the left
hemiazygos vein draining into the superior vena
cava, and nonocclusive thrombosis of the internal
jugular vein, mid and distal left subclavian vein, and
proximal left axillary veins. Vascular Surgery and
Hematology Oncology teams were consulted, and
the patient was initiated on a therapeutic dose of
unfractionated heparin for her occlusions.
A ﬂuoroscopy study was completed to determine
the patency of the chemotherapy port, which
demonstrated conﬁrmation of complete occlusion of
both lumens of the port ﬂush. Four days following
admission, the patient underwent IR-guided
removal of her chemotherapy port. The patient had
a follow-up Left Upper Extremity Venous Duplex
ultrasound which was signiﬁcant for negative DVT
ﬁndings in the left upper extremity and positive
ﬁndings
for
superﬁcial
thrombophlebitis.
Throughout her admission, she reported symptomatic improvement each day in terms of her
swelling and physical exam ﬁndings. The patient
was discharged on oral Apixaban 5 mg twice daily
with close outpatient Hematology Oncology clinic
follow-up and plans to continue chemotherapy via
peripheral line administration. Upon follow up, the
patient had complete resolution of her symptoms.
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3. Discussion
Despite the thrombogenic tendency of most malignancies, especially in patients who are actively
receiving chemotherapy treatment, the incidence of
chemo port-related thromboses has been shown to
be rather low. In a study involving over 51,000 individuals who underwent chemo port placement,
only 1.81% of these patients developed an upper
extremity venous thrombotic event (VTE).1 Additional studies have demonstrated a variable incidence of 1.75%e30.2% for patients who develop
VTE secondary to catheters.2 Nevertheless, removal
of the catheter is not always required according to
studies that have demonstrated a low incidence
(3.4%) of patients who require catheter removal
because of VTE.3 Our patient represents one of the
few individuals with a chemo port-related VTE
requiring the removal of her catheter.
Many trials have investigated whether patients
with indwelling catheters may beneﬁt from prophylactic warfarin (at either a ﬁxed dose or titrated
to achieve an INR goal of 1.5e2); however, these
studies have not demonstrated a signiﬁcant reduction in VTE.3 This evidence is further emphasized
by the American College of Chest Physician guidelines, stating there is no indication for chronic systemic anticoagulation as prophylaxis for VTE in
patients who have indwelling catheters placed.4
It has been shown that VTE secondary to chemo
ports has become more frequent in individuals who
use their chemo port for blood draws and anti-cancer treatment. In a retrospective study reviewing 80
patients with SVC syndrome, 21% of these patients
had VTE due to their chemo port. In this study, the
average age of presentation was 57.7 years old and
approximately 54% of the patients were females.5
When comparing our patient's demographics and
age, she was slightly younger than the anticipated
age for this phenomenon and represented the majority as a female who developed SVC syndrome.
Speciﬁc risk factors have been identiﬁed when it
comes to determining cancer patients who are at a
higher risk for the development of VTE. These factors include genetic mutations, age, gender, ethnic
background, grade and level of metastatic disease, as
well as speciﬁc types of cancer. In particular, patients
with pancreatic and brain malignancies have been
categorized as higher risk, with patients diagnosed
with lung and colon cancer moderate risk, and patients with breast and prostate cancer considered to
be a low risk.6,7 As our patient was diagnosed with
breast cancer, she remained at a lower risk for the
development of thrombotic events per this risk
stratiﬁcation. One study demonstrated that patients
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diagnosed with breast cancer who underwent
chemotherapy treatment were found to have a 47%
higher chance of developing thrombosis. Alternatively, the breast cancer patients who did not receive
chemotherapy were found to have a 26% increase in
thrombotic events. In this study, there were no signiﬁcant differences in thrombotic events between
patients who did versus did not proceed with surgical intervention (mastectomy or lumpectomy).8
Patients with chemo ports can develop thrombosis
via two different mechanisms, such as occlusion or
stenosis of the vein. This may occur due to
thrombus development at the tip of the catheter,
manipulation at the implantation site, malpositioning of the implanted port, or traumatic vessel injury
of the vein.9e11 Patients with a short catheter may
have malpositioning of the tip into the subclavian or
brachiocephalic vein (smaller diameters) which can
lead to the development of a ﬁbrin sheath and thus
increase the resistance of blood ﬂow when the
chemo port is used.9 Our patient had her chemo
port inserted to streamline receiving infusion therapy for her inﬂammatory breast cancer. Catheters
can be inserted in cancer patients to avoid frequent
sticks for blood draws and infusions; however, it is
essential to remember the serious risk factors of
these chemo ports.
Patients who develop catheter-related SVC syndrome can be managed in two ways. First, patients
can have their catheter removed and replaced by a
new, functional catheter.4,12,13 Alternatively, patients
can have a thrombolytic medication administered
into the non-functional catheter to lyse the occlusion,
which can be a less invasive and a less costly option.4,12,13 As there is no clear evidence that removal
of indwelling catheters will improve outcomes for
patients, patients may undergo removal only if their
catheter is no longer warranted, represents a clear
source of infection, or if it is no longer working
properly.4,14 In some cases, patients may have a
contraindication to antithrombotic therapy, have a
life-threatening thrombotic event where their limb
may be compromised, or may have a chronic occlusion that limits vein accessibility, and in these
cases, patients may beneﬁt from removal instead of
thrombolytic therapy.4,15 In our patient's case, she
began to experience neurological symptoms that
placed her in a higher risk category in addition to
her extensive intrathoracic venous occlusion on imaging, and her requirement for long-term central
venous access. Due to all of these factors, it was more
beneﬁcial for the patient to have her chemo port
removed instead of receiving thrombolytic therapy.
Regardless of whether patients undergo removal
of their chemo port, if they have cancer-related VTE,

systemic anticoagulation is warranted.16,17 Our patient was initiated on parenteral unfractionated
heparin for 4 days before IR-guided removal of her
chemo port, consistent with American College of
Chest Physicians (ACCP) guidelines who recommend removal of the catheter approximately three
to ﬁve days following anticoagulation therapy.16
Studies have demonstrated no signiﬁcant difference
in treatment of upper extremity DVT with warfarin
versus low-molecular-weight heparin;18 however,
current evidence demonstrates for patients with
cancer-associated thrombosis, low molecular weight
heparin is superior when compared to warfarin.19 In
this particular patient population, recent studies
have also included non-vitamin K oral anticoagulants for the treatment of cancer-related thrombosis
for both prophylaxis and treatment.20
Treatment duration for these patients remains a
controversial subject, where some clinicians
recommend a total of 3 months of treatment
following catheter removal, whereas others prefer a
shorter duration depending on the severity and
case-by-case basis.16 Ultimately, our patient had
improvement in her symptoms with an imageproven complete resolution of her thrombosis. Due
to her clinical improvement, she was discharged
with a three-month course of Apixaban, following
recent updates to the guidelines to utilize NOACs as
treatment of cancer-related thrombosis.
Although port-related thrombosis represents a
somewhat low incidence complication especially
with low risk factors, any unusual signs or symptoms need to be investigated. Our case was unique
due to lowered risk factors to develop thrombosis
when compared to older patients with other malignancies, which included the patient's age and
type of cancer. However, she developed a catheter
related thrombosis that progressed quickly to SVC
syndrome, an oncologic emergency.
A low threshold and more thorough examination
is required when unusual complaints are raised.
Multiple attempts to access the port could have
potentiated this complication. We recommend utilizing peripheral lines rather than ports for any
blood draws to avoid manipulating the port as much
as possible, and to ensure the patient is scheduled
for heparin ﬂushes in order to decrease risk.

4. Conclusion
Currently, evidence supporting the use of systemic anticoagulation therapy for preventative
measures of cancer-related thrombosis is lacking.
Patients with SVC syndrome secondary to their
chemo port can present acutely and may require

immediate removal or replacement of the catheter.
Management consists of treating the underlying
cause, and in our case, removal of the catheter and
anticoagulation was the appropriate treatment.
Additional research is warranted regarding the most
appropriate use of chemo ports and management of
cancer-related VTE. It would be beneﬁcial for each
hospital to establish local practice guidelines for
cancer-related VTE as well as establish measures to
prevent such complications in cancer patients.
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